期刊文献+

叶酸缺乏对乳腺癌化疗疗效和毒性的影响

The effect of folacin deficiency on the chemotherapy of breast cancer
下载PDF
导出
摘要 目的 :检测叶酸缺乏时化疗药物对人乳腺细胞株HBL 1 0 0和人乳腺癌细胞株MCF 7敏感性的影响。 方法 :将HBL 1 0 0和MCF 7在正常培养液和叶酸缺乏培养液中加入化疗药物 ,培养 3天 ,用四唑蓝 (MTT)法检测化疗药物对HBL 1 0 0和MCF 7的杀伤作用。 结果 :MCF 7对阿霉素 (ADM)、顺铂 (DDP)、氟尿嘧啶 (5 FU)、丝裂霉素(MMC)和甲氨蝶呤 (MTX)等化疗药物均不敏感。将 5 FU、MMC和MTX分别加入实验组和对照组培养液后 ,对照组中MCF 7细胞数减少 ,光密度值降低。ADM和DDP对MCF 7生长的抑制作用在两种培养液中无显著差异。ADM、DDP、5 FU、MMC和MTX等化疗药物 ,在两种培养液中 ,对HBL 1 0 0光密度值的影响无显著差异。 结论 :叶酸缺乏可以降低某些化疗药物如 5 FU、MMC和MTX对MCF 7的杀伤作用 ,但不改变ADM、DDP、5 FU、MMC和MTX等化疗药物对HBL 1 0 Objectives:To determine the effect of folacin deficiency on the chemotherapy of breast cancer lines MCF 7 and breast cell line HBL 100. Methods:These two cell lines were cultured for 3 days in the presence of chemotherapeutics.The MTT method was used for determination. Results: MCF 7 was not sensitive to ADM,DDP,5 FU,MMC or MTX. Treatment in vitro , there was no difference in cell numbers. Added with 5 FU,MMC or MTX, folacin deficiency decreased the growth of MCF 7. Folacin deficiency did not influence the effect of ADM,DDP,5 FU,MMC or MTX on HBL 100. Conclusions:Folacin synergizes the effect of 5 FU, MMC and MTX on the MCF 7 cell line.In the normal therapeutic range of ADM, DDP, 5 FU, MMC and MTX,folacin dificiency does not increase the toxic effects on the HBL 100 cell line.
出处 《肠外与肠内营养》 CAS 2003年第4期215-217,共3页 Parenteral & Enteral Nutrition
关键词 乳腺癌 叶酸缺乏 细胞培养 化疗 MTT法 药物毒性 Breast cancer Folacin deficiency Cell culture Cheotherapy
  • 相关文献

参考文献14

  • 1李克俭.亚叶酸钙与生化调节[J].中国癌症杂志,1999,9(1):54-55. 被引量:5
  • 2Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies [J]. Cancer Res, 1970,30 (4) :1174-1184.
  • 3Bradley G, Juranka PF, Ling V. Mechanism of multidrug resistance[ J]. Biochim Biophys Acta, 1988,948( 1 ) :87-128.
  • 4Fardel O, Lecureur V, Guillouzo A. The P-glycoprotein multidrug transporter[ J ]. Gen Pharmcol, 1996,27 (8) : 1283-1291.
  • 5Buttitta F, Marchetti A, Gadducci Aet al. p53 alterations are predictive of chemoresistance and aggressiveness in ovariau carcinomas: a molecular and immunohistochemical study [ J ]. Br J Cancer, 1997,75 (2) :230-235.
  • 6Righetti SC, Della TG, Pilotti Set al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma [ J ].Cancer Res, 1996 ,56(4) : 689-693.
  • 7Thottassery JV, Sun D, Zambetti GP et al, Spl and egr-1 have opposing effects on the regulation of the rat Pb, p2/mdr 1b gene[J]. J Biol Chem, 1999, 274(5) :3199-3206.
  • 8Thottassery JV, Zambetti GP, Arimori K et al. p53-depeudent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents[J]. Proc Natl Acad Sci USA,1997, 94(20) : 11037-11042.
  • 9Keshelava N, Zuo J J, Waidyaratne NS et al. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma[J]. Med Pediatr Oncol, 2000, 35(6) : 563-568.
  • 10Keshelava N, Zuo JJ, Chen Pet al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines [ J ].Cancer Res,2001,61 (16) :6185-6193.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部